The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Helena Alexandra Yu
Consulting or Advisory Role - Clovis Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Incyte (Inst); Pfizer (Inst)
 
Dennis Stephens
No Relationships to Disclose
 
Maria Catherine Pietanza
Honoraria - Celgene; Genentech
Consulting or Advisory Role - Celgene; Genentech
Speakers' Bureau - PER; Quintiles
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); OncoMed (Inst); Stem CentRx (Inst)
 
Stephanie Smith-Marrone
No Relationships to Disclose
 
John Joseph Fiore
No Relationships to Disclose
 
Melissa Goldstein
No Relationships to Disclose
 
Camelia S. Sima
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Exelixis; Genentech/Roche; Novartis; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Michelle S. Ginsberg
No Relationships to Disclose